Advertisement

Drugs

, Volume 78, Issue 10, pp 1025–1036 | Cite as

Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD

  • James E. Frampton
Adis Drug Evaluation

Abstract

Lisdexamfetamine dimesylate (lisdexamfetamine; Elvanse®; Tyvense®), an orally-active dexamfetamine prodrug, is indicated in the EU for the treatment of attention-deficit hyperactivity disorder (ADHD) in children aged ≥ 6 years (including adolescents) when the response to previous methylphenidate (MPH) treatment is clinically inadequate. The original approval of the drug was based on the results of phase III trials in children and adolescents with ADHD who had an inadequate response to previous pharmacotherapy (e.g. MPH) or were treatment naïve. In these studies, short-term treatment with flexibly-dosed lisdexamfetamine demonstrated greater efficacy than atomoxetine, based on a prospective comparison, and osmotic-release oral system (OROS)-MPH, based on a post hoc comparison. Improvements in ADHD symptoms were accompanied by improvements in health-related quality of life and functioning that were maintained as long as treatment with lisdexamfetamine was continued in a long-term extension of one of these trials. In subsequent phase IV head-to-head studies in adolescents with ADHD and an inadequate response to previous pharmacotherapy, lisdexamfetamine demonstrated greater efficacy than OROS-MPH when both medications were force-titrated, but not when they were flexibly-titrated. Lisdexamfetamine was generally well tolerated, with an adverse event profile (e.g. decreased appetite, headache, weight reduction, insomnia and irritability) typical of that reported for other stimulants. Thus, lisdexamfetamine provides an alternative option for the treatment of children and/or adolescents with ADHD who have not responded adequately to previous ADHD pharmacotherapies.

Notes

Acknowledgements

During the peer review process, the manufacturer of lisdexamfetamine was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

James Frampton is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Adesman A. The diagnosis and management of attention-deficit/hyperactivity disorder in pediatric patients. Prim Care Companion J Clin Psychiatry. 2001;3(2):66–77.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 3rd ed. New York: Guilford Press; 2006.Google Scholar
  3. 3.
    American Academy of Pediatrics. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–22.CrossRefGoogle Scholar
  4. 4.
    Danckaerts M, Sonuga-Barke EJS, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19(2):83–105.CrossRefPubMedGoogle Scholar
  5. 5.
    Wu E, Hodgkins P, Ben-Hamadi R, et al. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder. CNS Drugs. 2012;26(7):581–600.CrossRefPubMedGoogle Scholar
  6. 6.
    Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. 2018. https://www.nice.org.uk. Accessed 5 June 2018.
  8. 8.
    Huss M, Chen W, Ludolph AG, et al. Guanfacine extended release: a new pharmacological treatment option in Europe. Clin Drug Investig. 2016;36:1–25.CrossRefPubMedGoogle Scholar
  9. 9.
    Shier AC. Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. J Cent Nerv Syst Dis. 2013;5:1–17.CrossRefPubMedGoogle Scholar
  10. 10.
    Luan R, Mu Z, Yue F, et al. Efficacy and tolerability of different interventions in children and adolescents with attention deficit hyperactivity disorder. Front Psychiatry. 2017;8:229.  https://doi.org/10.3389/fpsyt.2017.00229.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Joseph A, Ayyagar R, Xie M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry. 2017;26:875–97.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Riera M, Castells X, Tobias A, et al. Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients. Psychopharmacology. 2017;234(17):2657–71.CrossRefPubMedGoogle Scholar
  13. 13.
    Lopez FA, Leroux JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. Atten Defic Hyperact Disord. 2013;5(3):249–65.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hodgkins P, Shaw M, McCarthy S, et al. The pharmacology and clinical outcomes of amphetamines to treat ADHD. CNS Drugs. 2012;26(3):245–68.CrossRefPubMedGoogle Scholar
  15. 15.
    Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15(8):476–95.CrossRefPubMedGoogle Scholar
  16. 16.
    Weber J, Siddiqui MA. Lisdexamfetamine dimesylate. CNS Drugs. 2009;23(5):419–25.CrossRefPubMedGoogle Scholar
  17. 17.
    Steer C, Froelich J, Soutullo C, et al. Lisdexamfetamine dimesylate. CNS Drugs. 2012;26(8):691–705.CrossRefPubMedGoogle Scholar
  18. 18.
    Shire Pharmaceutical Contracts Limited. Elvanse 20, 30, 40, 50, 60 & 70 mg capsules, hard. UK summary of product characteristics 2017. https://www.medicines.org.uk/emc/product/2979/smpc. Accessed 5 June 2018.
  19. 19.
    Frampton JE. Lisdexamfetamine: a review in ADHD in adults. CNS Drugs. 2016;30(4):343–54.CrossRefPubMedGoogle Scholar
  20. 20.
    Shire US inc. Vyvanse® (lisdexamfetamine dimesylate) capsules, for oral use. US prescribing information. 2015. https://www.accessdata.fda.gov. Accessed 5 June 2018.
  21. 21.
    Blick SK, Keating GM. Lisdexamfetamine. Paediatr Drugs. 2007;9(2):129–35.CrossRefPubMedGoogle Scholar
  22. 22.
    Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr. 2010;6:317–27.Google Scholar
  23. 23.
    Najib J. Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder. Adolesc Health Med Ther. 2012;3:51–66.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27(12):1081–92.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Coghill D, Banaschewski T, Lecendreux M, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23(10):1208–18.CrossRefPubMedGoogle Scholar
  26. 26.
    Coghill DR, Banaschewski T, Lecendreux M, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014;53(6):647–57.e1.Google Scholar
  27. 27.
    Coghill DR, Banaschewski T, Nagy P, et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: a phase IV, 2-year, open-label study in Europe. CNS Drugs. 2017;31:625–38.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Newcorn JH, Nagy P, Childress AC, et al. Randomized, double-blind, placebo-controlled acute comparator trials of lisdexamfetamine and extended-release methylphenidate in adolescents with attention-deficit/hyperactivity disorder. CNS Drugs. 2017;31:999–1014.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Shire. Effectiveness of Vyvanse compared to Concerta in adolescents with attention-deficit/hyperactivity disorder [ClinicalTrials.gov identifier NCT01552915]. US National Institutes of Health, ClinicalTrials.gov [online]. 2014. https://clinicaltrials.gov/ct2/show/NCT01552915. Accessed 5 June 2018.
  30. 30.
    Shire. Effectiveness of Vyvanse compared to Concerta in adolescents with attention-deficit/hyperactivity disorder [ClinicalTrials.gov identifier NCT01552902]. US National Institutes of Health, ClinicalTrials.gov [online]. 2015. https://clinicaltrials.gov/ct2/show/NCT01552902. Accessed 5 June 2018.
  31. 31.
    Nottinghamshire Area Prescribing Committee. Methylphenidate. Information sheet for primary care prescribers. 2016. http://www.nottsapc.nhs.uk. Accessed 5 June 2018.
  32. 32.
    Lecendreux M, Banaschewski T, Soutullo C, et al. Efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: effect of age, sex and baseline disease severity. In: 21st European Congress of Psychiatry; 2014.Google Scholar
  33. 33.
    Coghill DR, Banaschewski T, Lecendreux M, et al. Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial. Neuropsychiatr Dis Treat. 2014;10:2039–47.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Soutullo C, Banaschewski T, Lecendreux M, et al. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs. 2013;27(9):743–51.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Coghill DR, Banaschewski T, Lecendreux M, et al. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial. Eur Child Adolesc Psychiatry. 2014;23(2):61–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Banaschewski T, Soutullo C, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs. 2013;27(10):829–40.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Dittmann RW, Cardo E, Nagy P, et al. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs. 2014;28(11):1059–69.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Nagy P, Häge A, Coghill DR, et al. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention/deficit/hyperactivity disorder and an inadequate response to methylphenidate. Eur Child Adolesc Psychiatry. 2016;25(2):141–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Banaschewski T, Johnson M, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention deficit/hyperactivity disorder. CNS Drugs. 2014;28(12):1191–203.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Coghill D, Caballero B, Sorooshian S, et al. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28(6):497–511.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Banaschewski T, Johnson M, Nagy P, et al. Growth and puberty in a 2-year open-label study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs. 2018;32(5):455–67.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Coghill DR, Banaschewski T, Bliss C, et al. Cognitive function of children and adolescents with attention-deficit/hyperactivity disorder in a 2-year open-label study of lisdexamfetamine dimesylate. CNS Drugs. 2018;32(1):85–95.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Faraone SV, Spencer TJ, Kollins SH. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry. 2010;49(1):24–32.PubMedGoogle Scholar
  44. 44.
    Goodman DW. Lisdexamfetamine dimesylate. The first prodrug stimulant. Psychiatry (Edgemont). 2007;4(8):39–45.Google Scholar
  45. 45.
    Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother. 2008;9:1565–74.CrossRefPubMedGoogle Scholar
  46. 46.
    Ermer J, Adeyi B, Pucci M. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. CNS Drugs. 2010;24(12):1009–25.CrossRefPubMedGoogle Scholar
  47. 47.
    Weyandt LL, Marraccini ME, Gudmundsdottir BG, et al. Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants. Psychol Res Behav Manag. 2014;7:223–49.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Zimovetz EA, Beard SM, Hodgkins P, et al. A cost-utility analysis of lisdexamfetamine versus atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and inadequate response to methylphenidate. CNS Drugs. 2016;30(10):985–96.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Shire. Comparison of lisdexamfetamine dimesylate with atomoxetine HCl in attention-deficit/hyperactivity disorder (ADHD) subjects with an inadequate response to methylphenidate [ClinicalTrials.gov identifier NCT01106430]. US National Institutes of Health, ClinicalTrials.gov [online]. 2014. https://clinicaltrials.gov/ct2/show/study/NCT01106430. Accessed 5 June 2018.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations